This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Medivation: First Look At Xtandi Pre-Chemo Prostate Cancer Survival Curves

You're getting the first look at the Kaplan-Meier overall survival curves from the phase III "PREVAIL" study of Medivation (MDVN) and Astellas' Xtandi (enzalutamide) in pre-chemo prostate cancer patients. An update from the PREVAIL study was released tonight in advance of a formal presentation on Thursday at a medical conference.

Investors have been eager to see the Xtandi overall survival curves ever since Medivation and Astellas announced positive results and an early stop to the phase III study last November. As you can clearly see, a survival benefit favoring Xtandi (the green line) over placebo (blue line) starts early in the study at about four months and continues until the very end when the curves finally cross with only four patients remaining alive. 

As previously disclosed, the overall survival hazard ratio is 0.706, translating into a 29% reduction in the risk of death favoring Xtandi over placebo. Highly statistically significant. At the median, the overall survival benefit favoring Xtandi is 2.2 months over placebo.

Xtandi is competing against Johnson & Johnson's (JNJ) Zytiga in the pre-chemo prostate cancer treatment market. The two drugs have not been studied directly against each other but J&J did conduct its own phase III study of Zytiga plus prednisone versus prednisone alone. Data from this study have been presented at various medical meetings already.

For comparison purposes, here's what the Zytiga overall survival curves look like from its respective phase III study:


Notice: The Zytiga survival curve doesn't start to separate from the control arm until 18 months into the study. The hazard ratio for overall survival from the Zytiga study is 0.79, or a 21% reduction in the risk of death, favoring Zytiga over control. This survival result was not statistically significant because the study was stopped too early. 

The full presentation of the Xtandi PREVAIL data on Thursday will be made by Dr. Tomasz Beer of the Knight Cancer Institute at Oregon Health and Science University. Beer previewed his Xtandi presentation with the media earlier today, which is where these slides come from (with the exception of the abiraterone slide, which was shared with me by an investor who keeps better notes than I do.)

Medivation and Astellas did not comment on the new Xtandi data ahead of Thursday's presentation.

The co-primary endpoint of the Xtandi PREVAIL study was radiographic progression-free survival (rPFS.) Here's what those data look like:

This is the first look at the rPFS curves although the rPFS hazard ratio of 0.186 favoring Xtandi was previously disclosed. Obviously, the separation here is early, wide and very statistically significant. 

For the first time, Xtandi tumor response rate data are being shown.

Also for the first time, data showing treatment with Xtandi led to a significant delay in the median time to chemotherapy:


Here's a slide on Xtandi safety from the PREVAIL study:


Not noted on this slide is disclosure of two patients experiencing a seizure during the trial. According to Dr. Beer, one patient in each arm of the study reported a seizure (1 in the Xtandi arm, 1 in the placebo arm) and both patients entered the study with a history of seizures not known to investigators at that time. 

Beer characterized the seizure rate seen in the PREVAIL study as "extremely low" and "very reassuring."

Lastly, here is the conclusion slide from Beer's presentation of the Xtandi data earlier today:

The Xtandi data are being presented Thursday at the 2014 Genitourinary Cancers Symposium, sponsored by the American Society of Clinical Oncology, the American Society for Radiation Oncology and the Society of Urologic Oncology. 

Based on the data from the PREVAIL study, Medivation and Astellas will be seeking regulatory approval to expand the Xtandi label to include treatment of prostate cancer patients who have not been treated with chemotherapy. [The drug is already approved in the post-chemo prostate cancer setting.]

Astellas reports results from its most recent quarter on Feb. 2. The current consensus for U.S. Xtandi sales in the fourth quarter is $111 million. Astellas and/or Medivation are also expected to provide Xtandi sales guidance for 2014. Current consensus stands at $636 million, according to J.P. Morgan. 

-- Reported by Adam Feuerstein in Boston.  

Follow Adam Feuerstein on Twitter.

Stock quotes in this article: MDVN, JNJ 
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs